A Women in Pharma Event: A Transformational Air Purification Technology and Paradigm Shift in Healthcare and Life Sciences

Within life sciences, the LifeAire System has been proven to improve cell growth and viability and will positively impact cell culture success rates, increasing the number of successful deliveries of a cellular product to the patient. LifeAire is more than just a world class air purification technology. It is a process that will help to achieve and maintain the highest level of air purity in the world today. Getting to this level involves addressing issues across an array of areas: cytotoxic airborne pollutants, operating environments, SOPs, building and construction materials, etc.

Case studies show that volatile organic compounds (VOCs) and low levels of viable particulates, bacterial and viral, have detrimental effects on cell viability and growth. VOCs are common airborne constituents of outside source air, recirculated laboratory air, HVAC components, tissue culture ware, and cell culture procedures.  Cytotoxic VOCs play a critical role in cell arrest, delay and mortality. Research has demonstrated that a large range of VOCs exist within biopharmaceutical processing facilities and cause cytotoxicity by perturbing cellular membranes, increasing intracellular calcium ions, impairing mitochondrial function, increasing DNA oxidative damage, increasing DNA fragmentation, and interfering with DNA and RNA replication processes. Significant research by Dr. Worrilow and her colleagues has defined the airborne metrics critical in the consistent support of the cultured living cell.

Specific to healthcare, because the System was designed to provide a significant log level reduction of infectious airborne bacterial, viral and fungal spores, responsible for a large percentage of subclinical illness and healthcare acquired infections, the LifeAire System has recently been implemented in the protection of patients in a medical surgical setting. After implementation for 12 months, the impact of the technology resulted in a statistically significant reduction in length of stay, increased capacity and throughput, and improved discharge and healthcare economic metrics. VOC remediation was critical in those patients suffering from COPD and similar respiratory compromise. The study shared the significance of the clinical environment and its impact on clinical and economic metrics.


Kathryn Colonna Worrilow

Dr. Kathryn Colonna Worrilow

Dr. Kathryn Colonna Worrilow received her bachelor’s degree in Biology and Mathematics at Randolph Macon Women’s College. She received her Ph.D. in Anatomy and Cell Physiology from the University of Virginia School of Medicine and went on to pursue her post-doctoral fellowship in Reproductive Physiology and Infertility at the University of Pennsylvania School of Medicine.

Dr. Worrilow was the Scientific Director of In Vitro Fertilization and Andrology Laboratories for over 20 years, the Managing Director at KC Worrilow and Associates for 4 years and served as an Adjunct Professor at The Pennsylvania State University Lehigh Valley for several years as well as the Founder and CEO of LifeAire Systems, LLC since 2010.

Working with a team of chemists, engineers, and physicists, Dr. Worrilow developed the LifeAire System. Its proprietary, staged, and patented technology comprehensively addresses airborne chemical and biological pathogens. It is quite simply, the most powerful defense a laboratory or cleanroom can employ, and your fastest path to a significant improvement in cellular and patient outcomes.

Registration Information:



ISPE Members




Young Professional/Student/Retired 


Webcast Only (ISPE Members) $40

Register Now

*On-site registration will incur $20 surcharge. Please note, while we will do our best to accommodate walk-in registrants, meals and/or preferred entree selection are not guaranteed; kindly register by Friday, March 6 to guarantee preferred entree selection.